Thread: I can't help but notice all the articles and what's next for #psychedelics. It's honestly fantastic that @PattyHajdu did the right thing for dying patients!

I do wish though that the media would talk about the regulatory process as well as access for patients more.

Here's a regulatory summary and information on how patients with exemptions can access these compounds along with a question I'd wish the media wrote about and asked @GovCanHealth:

1) In Canada, psilocybin and psilocin, which are substances found in ‘magic mushrooms’, are controlled under Schedule III of the Controlled Drugs and Substances Act (CDSA) and regulated under Part J of the Food and Drug Regulations (FDR).

2) As long as the licenced dealer (LD) has the substance on their licence, and selling to subsection 56(1) exemption holders is one of the activities authorized on the LD’s licence,

There are no additional requirements besides the subsection 56(1) exemption letter issued to the exemption holder, informing the LD.

3) Some LDs may have certain restrictions attached to their licence in selling to exemption holders. (Not all LD's can sell to exemption holders)

4) It would be good to get a list (even how many, #) of LD's have licences for these compounds (not just for R&D) but more importantly how many LD's have sale licences for these compounds?

C.C: @JaneCStevenson @sismondo @johnsemley3000 @picardonhealth

@threadreaderapp roll up please.